Drawing for PROLEEV

USPTO serial 85704119

PROLEEV

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
PENDLETON, CAROLYN A
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PROLEEV?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nicole Gage

NICOLE GAGE FOLEY & LARDNER LLP111 HUNTINGTON AVE STE 2600BOSTON, MA 02199-7682UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations, namely psychotropicsABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 29, 2013MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Jan 29, 2013ABN5ABANDONMENT - AFTER PUBLICATION—
Jan 22, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 22, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 17, 2013EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Jan 2, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 11, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 11, 2012DOCKASSIGNED TO EXAMINER—
Aug 22, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 18, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance